Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × HhAntag691 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Synovial 1 Sarcoma, Kaposi 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Osteosarcoma 1 Neurofibrosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms 1 Microphthalmia, Isolated, with Coloboma 5 1 Medulloblastoma 1 Malignant mesenchymal tumor 1 Liposarcoma 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Fibrosarcoma 1 Desmoplastic Small Round Cell Tumor 1 Dermatofibrosarcoma 1 Chondrosarcoma, Extraskeletal Myxoid 1 Chondrosarcoma 1 Carcinoma, Basal Cell 1

Interventions

Temozolomide 65 Radiotherapy 26 Bevacizumab 23 Carboplatin 12 Radiation 11 pembrolizumab 10 Irinotecan 7 Carmustine 7 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 Nivolumab 5 Everolimus 5 temsirolimus 4 atezolizumab 4 Vorinostat 4 Radiotherapy, Intensity-Modulated 4 Lomustine 4 Aminolevulinic Acid 4 tipifarnib 3 fludarabine 3 Sirolimus 3 Radiotherapy, Conformal 3 Paclitaxel 3 Magnetic Resonance Spectroscopy 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3 Drug Therapy 3 Cyclophosphamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03158389 2023-09-28

N²M²

University Hospital Heidelberg

Phase 1/2 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡